Targeted Liposomal Nano-Therapy Combats Ehrlich Ascites Carcinoma with Reduced Toxicity and Enhanced Anticancer Efficacy

Strategic Insights -

Researchers at Ain Shams University have made groundbreaking findings in the treatment of Ehrlich ascites carcinoma (EAC), a rapidly growing tumor model, by developing targeted liposomal nano-therapy combining anthocyanin and cisplatin. This innovative approach not only reduces systemic toxicity but also enhances anticancer efficacy against EAC, demonstrating a promising future for cancer therapy.

Key Takeaways:

  • The study found that anthocyanin-loaded liposomes (Ant Ls) achieved a high encapsulation efficiency of 93.06% and exhibited sustained release profiles, achieving the highest cumulative drug release of 59.11% at 48 hours.
  • Cisplatin-loaded liposomes (Cis Ls) and their combination with Ant Ls demonstrated significant cytotoxicity against HCT 116 and Vero cells, with a 50% reduction in cell viability.
  • Serum biochemical markers (ALT, AST, urea, and creatinine) were significantly reduced in animals treated with Cis Ls and Ant Ls, indicating mitigation of liver and kidney damage.
  • The study analyzed various genes related to EAC progression, including apoptotic (caspase-3, Bcl2), inflammatory (IL1b), angiogenic (VEGF), metastatic (MMP9), and antioxidant (Nrf2, HO-1) genes, revealing a decrease in EAC burden.
  • The researchers emphasized the importance of targeting and reducing systemic toxicity through liposomal drug delivery, which enhances bioavailability and reduces side effects.
  • Funders for this research include Northern Border University and Princess Nourah Bint Abdulrahman University.

Statistics:

  • 93.06% encapsulation efficiency of Ant Ls.
  • 59.11% cumulative drug release of Ant Ls at 48 hours.
  • 50% reduction in cell viability of HCT 116 and Vero cells treated with Cis Ls and Ant Ls.
  • Significant reduction (P < 0.05) in serum biochemical markers (ALT, AST, urea, and creatinine) in animals treated with Cis Ls and Ant Ls.

Sources:

  • Targeted liposomal nano-therapy combining anthocyanin and cisplatin reduces Ehrlich ascites carcinoma burden. Frontiers in Pharmacology, 2025;16:1659575.
  • NewsRx. Data on Cancer Gene Therapy Reported by Researchers at Ain Shams University (Targeted liposomal nano-therapy combining anthocyanin and cisplatin reduces Ehrlich ascites carcinoma burden). Cancer Weekly. November 4, 2025; p 5.